Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the enrollment of the first patients in a Phase 2 extension trial of its investigational shingles vaccine, amezosvatein.

“I’m so proud of the Curevo team’s drive to get amezosvatein to people looking for a shingles vaccine alternative,” stated Dr. Guy De La Rosa, Chief Medical Officer for Curevo. “We are also proud to be working with a great collection of clinical trial sites, whose excitement for this trial and the overall potential of amezosvatein is gratifying.”

“To enroll our first patients just over two months after announcing our $110 million Series B round demonstrates the Curevo team’s ability to execute quickly,” added George Simeon, Curevo’s CEO.

The Phase 2 extension includes the key population of adults over age 70, targeting randomization of 640 participants to receive amezosvatein or Shingrix^®, the currently approved shingles vaccine. Endpoints in the trial include immunogenicity, reactogenicity, and safety. This extension of Curevo’s existing successful Phase 2 program was designed based upon feedback from regulators and other stakeholders to finalize dose selection ahead of the Phase 3 program and is intended to position the company for clinical, strategic, and regulatory success.